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Background: The porphyrias are a heterogeneous group of rare metabolic diseases. The full spectrum of porphyria
diagnostics is usually performed by specialized porphyria laboratories or centres. The European Porphyria Initiative
(EPI), a collaborative network of porphyria centres formed in 2001, evolved in 2007 into the European Porphyria
Network (EPNET), where participating centres are required to adhere to agreed quality criteria. The aim of this study
was to examine the state and distribution of porphyria diagnostic services in 2009 and to explore potential effects
of increased international collaboration in the field of these rare diseases in the period 2006–2009.
Methods: Data on laboratory, diagnostic and clinical activities and services reported to EPI/EPNET in yearly activity
reports during 2006 through 2009 were compared between reporting centres, and possible time trends explored.
Results: Thirty-five porphyria centres from 22 countries, five of which were non-European associate EPNET
members, filed one or more activity reports to EPI/EPNET during the study period. Large variations between centres
were observed in the analytical repertoire offered, numbers of analyses performed and type and number of staff
engaged. The proportion of centres fulfilling the minimum criteria set by EPNET to be classified as a specialist
porphyria centre increased from 80% to 94% during the study period.
Conclusions: Porphyria services are unevenly distributed, and some areas are probably still lacking in specialized
porphyria services altogether. However, improvements in the quality of diagnostic services provided by porphyria
centres participating in EPI/EPNET were observed during 2006 through 2009.
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The porphyrias are a heterogeneous group of rare meta-
bolic diseases caused by abnormal function in one of
the eight enzymes of the haem biosynthetic pathway,
leading to overproduction and accumulation of haem
precursors [1]. Symptoms of disease can present as
acute attacks of abdominal pain and neuropsychiatric
symptoms (acute intermittent porphyria (AIP) and
δ-aminolevulinic acid (ALA) dehydratase deficiency),
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reproduction in any medium, provided the orerythropoietic protoporphyria (EPP), X-linked dominant
protoporphyria (XLDPP) and congenital erythropoietic
porphyria (CEP)) or both (hereditary coproporphyria
(HCP) and variegate porphyria (VP)). Acute attacks can be
triggered by various factors such as many commonly used
drugs, alcohol, hormonal changes, infectious disease and
fasting, while cutaneous symptoms are triggered by expos-
ure to light. In symptomatic patients, diagnosis depends
on the biochemical detection of haem precursor accumu-
lation in blood, urine and faeces [1]. The three most com-
mon acute porphyrias, AIP, VP and HCP, are inherited in
an autosomal dominant fashion with low clinical pene-
trance, and presymptomatic DNA testing is often offered
for identification of healthy at-risk relatives. Because of
the complexity of diagnosing these disorders, the fulll Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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performed by specialized porphyria laboratories or cen-
tres, but general laboratories might offer some front-
line porphyrin analyses. The porphyrias are probably
under-diagnosed, as are many other rare inherited
metabolic diseases [2], and the availability and quality of
porphyria diagnostics and services might vary both
within and between countries.
The European Porphyria Initiative (EPI) was formed in
2001 as a collaborative network of porphyria centres in
Europe, with non-European centres participating as asso-
ciate EPI members [3]. In 2007, the work of EPI was fur-
ther continued and expanded and the European Porphyria
Network (EPNET) was formed [4]. EPNET was estab-
lished, initially as a three-year project funded by the
European Commission through its Public Health and
Consumer Protection Directorate, with the aim of setting
up an effective European network consisting of specialist
porphyria laboratories and diagnostic centres adhering to
agreed quality criteria [5]. EPNET began its work by fo-
cusing on seven work packages (WP), of which the first
three had administrative purposes. The aims of WP6
were to collect data about the European specialist por-
phyria centres’ activities and workload and give feedback
to the centres comparing their activity levels to the
others’, to set up a clinical and analytical external quality
assessment (EQA) scheme, to develop uniform quality
standards and to draw up consensus-agreed protocols for
porphyria diagnostics and monitoring.
The aim of the present study was to use the yearly
reported activity data collected as a part of the EPNET
project’s WP6 to examine the state and distribution of
porphyria diagnostic services among participating cen-
tres, and to explore potential effects of increased inter-
national collaboration in the field of rare diseases.
Methods
Since 2003/2004, EPI/EPNET centres and associate non-
European members have been required to submit yearly
reports with data on the number of biochemical and gen-
etic laboratory analyses performed, individuals investigated
and/or request forms received, new diagnoses made, type
of clinical services provided, description of staff involved,
participation in external quality assessment (EQA) pro-
grammes and accreditation/certification status of the la-
boratory facilities. New diagnoses reported include the
number of new symptomatic porphyria patients as well as
the number of presymptomatic cases identified, i.e. muta-
tion carriers identified based on DNA testing of healthy
at-risk relatives. From 2005 onwards, the centres have
been evaluated with regard to whether their services fulfil
an agreed set of quality criteria. These include a) the abil-
ity to perform the following biochemical analyses: in urine;
ALA, porphobilinogen (PBG) and total porphyrins withfractionation, in faeces; total porphyrins with fractionation
including separation of coproporphyrin isomers I and III,
in blood; erythrocyte protoporphyrin and plasma fluores-
cence scanning, b) participation in a relevant EQA
programme (from 2009 onwards), and c) providing labora-
tory reports that include a detailed interpretation of the la-
boratory results and incorporate expert clinical advice.
Since 2006, individual feedback reports have been pro-
vided to the centres, comparing each centre’s level of ac-
tivity to that of the other participating centres.
In the present study, the summary statistics of the
2009 feedback reports were used to examine the state
and distribution of porphyria diagnostic activities and
services this year. For the 12 countries where the partici-
pating porphyria centres reported that they provide na-
tional coverage of porphyria diagnostics in 2009, and
where all the relevant data had been reported, numbers
of individuals investigated per 100,000 inhabitants and
the numbers of new AIP and PCT diagnoses per
100,000 inhabitants were also calculated. In addition,
data from the 2006–2009 feedback reports were used to
investigate trends and developments in laboratory ana-
lyses and diagnostic services offered, number of centres
fulfilling the EPNET specialist porphyria centre criteria
as well as numbers of new porphyria diagnoses reported
in Europe.
Results
A total of 35 porphyria centres from 22 countries, five of
which were non-European, reported their activity data to
EPNET during the study period (Table 1). However, not
all centres reported data each year, nor did all centres re-
spond to every question when participating.
With regard to laboratory services offered, urinary
ALA and PBG were the only two biochemical analyses
offered and performed by all responding centres every
year (Table 2). Urinary PBG is the primary front-line ana-
lysis for diagnosing the three most common acute por-
phyrias (AIP, VP and HCP), but plasma fluorescence
scanning and estimation of the faecal coproporphyrin III:
I ratio must be performed to adequately differentiate be-
tween them [6]. During the study period, the proportion
of reporting centres that were able to, and had performed
faecal porphyrin fractionation including coproporphyrin
isomer I and III differentiation, increased from 77% to
85% (Table 2). Similarly, there was an increase in the pro-
portion of responding centres performing erythrocyte
protoporphyrin analyses with the distinction between
metal free and zinc-chelated protoporphyrin, from 67%
in 2006 to 79% in 2009. Eighty-three percent of reporting
centres had performed plasma fluorescence scanning in
2006 compared to 88% in 2009. The proportion of cen-
tres preforming DNA- analyses, however, was relatively
stable over time.
Table 1 Porphyria centres providing activity data to EPNET from 2006 through 2009
Country Porphyria centre 2006 2007 2008 2009
Australia NSW Porphyria Reference Unit, Royal Prince Alfred Hospital, Camperdown X X X X
Belgium Centre Belge des Porphyries, Hôpital Erasme - ULB, Brussels X X X X
Metabool Centrum, UZ Gasthuisberg, Leuven X X X X
Brazil Clinics Hospital of Ribeirao Preto, São Paulo X
Czech
Republic
National Laboratory for Porphyric Disease, 1st Medical Faculty, Charles University of Prague X X X X
Denmark Danish Porphyria Center, Viborg Regional Hospital X X X X
Finland Porphyria Research Centre in Finland, University Central Hospital of Helsinki X X X
France Centre Francais des Porphyries, Hospital Louis Mourier (APHP), Colombes X X X X
Germany Deutsches Kompetenz-Zentrum für Porphyriediagnostik und Konsultation, MVZ Labor Prof. Seelig, Karlsruhe X X X X
Hospital of the University of Munich X X X X
Porphyria Specialist Center Düsseldorf, University Hospital Düsseldorf X X X X
Porphyria Center Saxony, Klinikum Chemnitz gGmbH X X X X
Hungary Hungarian Porphyria Center, Ministry of Defence National Health Center, Budapest X X X
Porphyrin Laboratory, University of Szeged X X X X
Ireland Irish Porphyria Specialist Centre, St. James´s Hospital, Dublin X X X X
Israel National Service for the Biochemical Diagnosis of Porphyrias, Rabin Medical Centre, Beilinson Hospital,
Petah Tikva
X X X X
Italy U.O. Medicina Interna Ia, IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan X X X X
Laboratorio di Diagnostica Delle Porfirie e Delle Aminoacidopatie, Dipartimento integrato di Medicine e
Specialita Mediche, University of Modena and Reggio Emilia
X X X X
Porphyria Centre and Hereditary Metabolic Diseases, San Gallicano Institute IRCCS Rome X X X X
Interregional Reference Centre for prevention, surveillance, diagnosis and therapy of porphyrias, "Casa




Euregional Porphyria Center Maastricht (EPCM), Maastricht University Medical Center X
Porphyria Center Rotterdam, Erasmus Medical Center, Rotterdam X X X X
New
Zealand
Porphyria centre, Canterbury Health Laboratories, Christchurch X X X
Norway Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital, Bergen X X X X
Poland Laboratory of Porphyria, Institute of Hematology and Transfusion Medicine (IHiT), Warsaw X X X X
South
Africa
UCT Lennox Eales Porphyria Labs, UCT Medical School, Cape Town X X X X
Spain Porphyria Unit, Hospital Clinic, University of Barcelona X X X X
Porphyria Unit, Hospital Universitario Doce de Octubre, Madrid X X X X
Sweden Porphyria Centre Sweden, Karolinska University Hospital, Stockholm X X X X
Switzerland Porphyrie-Referenzlabor, Stadtspital Triemli Zürich X X X X
United
Kingdom
Cardiff SAS Porphyria Service, University Hospital of Wales, Cardiff X X X X
Leeds Teaching Hospitals NHS Trust, Leeds X X X
Porphyria Laboratory, King’s College Hospital, London X X X X
Salford Royal NHS Foundation Trust, Salford X X X X
USA Porphyria Center, University of Texas Medical Branch, Galveston X X X X
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Table 2 Number of participating EPNET centres and associate members having performed diagnostic laboratory
analyses during 2006 through 2009
Material Analyte 2006 2007 2008 2009
(30 centres) (32 centres) (32 centres) (33 centres)
Urine ALAa 30 32 32 33
PBGa,b 30 32 32 33
Total porphyrinsa 25 27 28 29
Fractionation of porphyrinsa,c 30 30 31 31
Faeces Total porphyrinsa 22 21 23 26
Fractionation of porphyrins with separation of copro I/IIIa,b,c 23 25 28 28
Fractionation of porphyrins without separation of copro I/III 9 5 5 5
Plasma Plasma fluorescence scanninga,b,c 25 29 29 29
Total porphyrins 11 13 15 16
Fractionation of porphyrins 16 9 11 11
ALA not asked not asked not asked 3
PBG not asked not asked not asked 3
Whole blood Erythrocyte total protoporphyrina,d 23 27 28 30
Erythrocyte free and zinc-chelated protoporphyrin a,d 20 24 23 26
Porphobilinogen deaminase activity 20 22 22 23
Uroporphyrinogen decarboxylase activity 12 9 7 10
Other enzyme analysese 12 12 8 10
DNA analyses Hydroxymethylbilane synthase gene 19 16 18 17
Uroporphyrinogen III synthase gene 8 3 1 9
Uroporphyrinogen III decarboxylase gene 13 10 10 12
Coproporphyrinogen III oxidase gene 11 13 13 12
Protoporphyrinogen oxidase gene 19 17 18 17
Ferrochelatase gene 16 13 14 15
ALA synthase 1 gene not asked not asked 0 1
ALA synthase 2 gene not asked not asked 4 7
a Minimum laboratory analyses required for being classified as an EPNET specialist porphyria centre.
b Considered necessary for the diagnosis and discrimination of the three most common acute porphyrias (acute intermittent porphyria, hereditary coproporphyria
and variegate porphyria).
c Considered necessary for the diagnosis and discrimination of cutaneous porphyrias with active skin lesions (not including EPP).
d Two out of three (total, free and/or zink-chelated protoporphyrin) considered necessary for the diagnosis of EPP.
e Other enzymes comprise ALA dehydratase, ALA synthase, uroporphyrinogen III synthase, coproporphyrinogen oxidase, protoporphyrinogen oxidase and
ferrochelatase.
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tory analysis in 2009, with centres performing between 23
and 1342 (median 255) analyses (data not shown). Nine
out of 33 reporting centres analysed less than 200 PBG
samples, whereas five laboratories analysed more than
1000 samples. Urinary total porphyrins was the second
most frequently performed analysis, with half of the cen-
tres performing this analysis more frequently than PBG.
Twenty-eight out of the 33 reporting centres were able to
perform one or more enzyme activity analysis, and 19
offered DNA analysis for one or more porphyria diseases.
With regard to human resources available to the par-
ticipating porphyria centres in 2009, the median number
of whole time equivalent (WTE) employees was 3.9(range 0.3-10.7). The majority of the employees con-
sisted of medical laboratory technologists, biomedical
scientists and technicians. Four centres had less than
one WTE employee, while seven centres had eight or
more. Thirty out of 33 centres reported the employment
of one or more physicians, with a median WTE of 0.95
(range 0.05-4.0). Twelve centres reported a median of
0.75 WTE of nurses (range 0.04-2.0).
In 2009, twelve centres in eleven countries reported that
they provide national coverage of porphyria diagnostics in
their respective countries (in Hungary by combination of
two centres) and also reported the numbers of individuals
they had investigated this year. The number of individuals
investigated included both suspected new cases of
Figure 1 Numbers of individuals investigated per 100,000 inhabitants in 2009. Numbers of individuals investigated per 100,000 inhabitants
in 2009 in countries where EPNET porphyria centres or associate members reported relevant data and national coverage of porphyria diagnostics.
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numbers of individuals investigated per 100,000 inhabi-
tants in these countries ranged from less than three in
France, Poland and the Netherlands to 15 in Norway
(Figure 1).
The numbers of new diagnoses made per 100,000 inha-
bitants of the most common porphyrias, AIP and PCT,
also varied greatly between centres with reported national
coverage of porphyria diagnostics in 2009 (Figure 2). The
highest rates of new PCT diagnoses (presymptomatic plus
symptomatic) per 100,000 inhabitants were found in Norway
(0.73), Sweden (0.42) and France (0.37). Sweden and Norway
also had the highest numbers of new AIP diagnoses perFigure 2 New diagnoses of PCT and AIP per 100,000 inhabitants in 20
intermittent porphyria (AIP) per 100,000 inhabitants in 2009 in countries wh
coverage of porphyria diagnostics, shaded areas representing presymptom100,000 inhabitants (0.30 and 0.27, respectively), followed
by Poland (0.21).
The proportion of presymptomatic PCT diagnoses rela-
tive to all new PCT diagnoses was low in all countries,
whereas greater variation in symptomatic versus presymp-
tomatic cases of new AIP diagnoses was evident. Some
centres reported almost exclusively presymptomatic new
cases of AIP, whereas others reported only new symptom-
atic cases.
With regard to new porphyria diagnoses reported in
Europe from 2006 through 2009, PCT was the most fre-
quently diagnosed porphyria overall (Figure 3), while AIP
was the most frequently diagnosed acute porphyria. The09. New diagnoses of porphyria cutanea tarda (PCT) and acute
ere EPNET porphyria centres or associate members reported national
atic cases.
Figure 3 Reported new porphyria diagnoses in Europe from 2006 to 2009. Reported numbers of new porphyria diagnoses in Europe from
2006 through 2009, shaded areas representing presymptomatic cases.
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matic cases increased from 58% to 69% during the four
year period. In 2006, 15 centres reported presymptomatic
AIP cases, with nine centres reporting more presymp-
tomatic than symptomatic cases. In 2009, 17 centres
reported new presymptomatic AIP cases, of which 11 cen-
tres reported more presymptomatic than symptomatic
cases. Ten centres reported new presymptomatic cases of
PCT in 2006, compared to nine in 2009. The proportion of
presymptomatic diagnoses of PCT remained close to 10%
throughout the four years.
The proportion of EPNET centres and associate mem-
bers’ laboratories participating in EQA schemes increased
from 47% in 2006 to 85% in 2009 (Table 3). The propor-
tion of centres reporting to have accredited or certified la-
boratory facilities increased from 47% in 2006 to 67% in
2009. In 2006, 24 out of 30 participating centres (80%)Table 3 Number of porphyria centres fulfilling the minimum
classified as specialist porphyria centres, reporting participat
and having accredited and/or certified laboratory facilities
2006
(n = 3
Fulfilling minimum criteria 24a
Participation in EQAS for metabolites and/or enzymesb 14
Accredited and/or certified laboratoryc 14
aTwo centres were considered specialist porphyria centres in conjunction with anot
bPart of the minimum criteria from 2009 onwards. Reported EQA schemes:
Royal College of Pathologists of Australasia Quality Assurance Programs (RCPA-QAP
EQAS), Welsh External Quality Assurance Scheme (WEQAS), Society for Promotion o
Centre Switzerland (CSCQ), Dutch Foundation for Quality Assessment in Clinical Lab
cReported standards: ISO 9001, ISO 14001, ISO 17025, ISO15189, CPA (UK), CAP/CLIAfulfilled the minimum criteria for being classified as a spe-
cialist porphyria centre. By 2009, 94% fulfilled the criteria.
Discussion
The porphyrias are rare diseases that can be complicated
to diagnose, and in most European countries the full
spectrum of porphyria diagnostics is offered by national or
specialized porphyria laboratories or diagnostic centres.
Since 2001, many such porphyria centres have been co-
operating under the EPI/EPNET, with non-European cen-
tres participating as associate members, striving to adhere
to agreed quality criteria. This study shows that in 2009
there were large variations between porphyria centres with
regard to the numbers and type of laboratory analyses per-
formed, workload and dedicated personnel available. How-
ever, from 2006 through 2009 there was evidence of
improvements in the analytical repertoire offered byanalytical and clinical criteria set by EPNET to be
ion in external quality assurance schemes (EQAS)
2007 2008 2009





), European Porphyria Network External Quality Assessment Scheme (EPNET
f Quality Assurance in Medical Laboratories (INSTAND e.V.), Quality Control
oratories (SKLM).
, ISO 9000, ISO 17089.
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bers of participating centres fulfilled the minimum criteria
for being classified as an EPNET specialist porphyria
centre; by 2009 94% fulfilled them.
As a part of EPNET’s WP6, the EPNET EQA scheme
was established in 2008. Twice a year, biological specimens
from a porphyria patient are distributed along with a case
history to participating laboratories. The scheme covers
diagnostic strategies, analytical laboratory performances,
the clinical interpretation and reporting of results. Evalu-
ation of the programme revealed large variations with
regard to analytical and diagnostic performances [7]. How-
ever, regular participation rapidly led to improvements in
diagnostic strategies and more uniformly use of standar-
dized units. The present study confirms that from 2006
through 2009, there was evidence of improvements in
analytical laboratory services offered. The differentiation
between the faecal coproporphyrin isomers I and III is of
particular importance when diagnosing or excluding the
rare HCP [6], and more centres could perform this ana-
lysis over time, and did so increasingly. Similarly, an in-
creasing number of centres was able to distinguish
between metal free and zinc-chelated protoporphyrin.
This is of importance when diagnosing EPP [8], particu-
larly in patients with a low erythrocyte protoporphyrin
concentration and when differentiating between XLDPP
caused by a mutation in ALA synthase 2 gene [9] and EPP
caused by mutations in the ferrochelatase gene. Also,
more centres offered plasma fluorescence scanning during
the study period. This analysis is necessary to discriminate
between both cutaneous and acute porphyrias, and of par-
ticular importance when diagnosing VP.
Having observed that more centres were able to per-
form essential laboratory analyses over time, we sought
to investigate if centres that had introduced new ana-
lyses had in fact diagnosed and reported more cases of
the relevant porphyrias. We were, however, not able to
confirm any such trends (data not shown). HCP, EPP
and VP are rare porphyrias of which most centres iden-
tify only a few new cases each year, some years none.
Making the correct diagnosis in a symptomatic porphy-
ria patient is a complex process, where offering the cor-
rect laboratory analyses is an essential, but not sufficient
prerequisite. The clinician first has to suspect porphyria
and send adequate biological samples to a diagnostic
centre. After having performed and interpreted correctly
the necessary laboratory analyses, the diagnostic centres
can confirm or exclude the diagnosis. With such small
numbers of new diagnoses reported each year, it is not
surprising that an observed trend of improvement in la-
boratory analyses offered alone is not enough to show
an improved ability to diagnose certain porphyrias. Still,
we believe this to be an important step in the right dir-
ection for better care for porphyria patients.In addition to the observed improvements in laboratory
analyses offered by EPNET centres and associate members,
improvement was evident from the increasing proportion
of centres fulfilling the minimum criteria for being classified
as a specialist porphyria centre, laboratories participating in
EQA schemes and reporting to have accredited or certified
facilities. The increased awareness of the porphyrias caused
by the efforts of EPI/EPNET, the yearly activity feedback
reports that may serve as a reminders of best practise and
turn attention to areas where each centre might focus their
efforts to improve their services, and the establishment of
the EPNET EQA scheme in 2007 [7] may be, at least in
part, responsible for the observed improvements.
A considerable variation in numbers of individuals inves-
tigated per 100,000 inhabitants was observed between the
11 countries where participating centres reported that they
provide national coverage of porphyria diagnostics, ranging
from less than three to 15. The numbers of individuals
investigated included both suspected new cases of porphy-
ria as well as monitoring of known patients. The observed
variation could therefore partly reflect the clinicians’ vary-
ing awareness of the porphyrias and willingness to send
biological samples for testing. Also, routines for follow-up
and monitoring of known patients differ between coun-
tries. For instance, where recommendations are made to
analyse yearly control samples from patients in remission,
as well as monitoring more frequently when symptoms
occur, as in Norway, a relatively larger number of indivi-
duals investigated per 100,000 inhabitants are to be
expected. Where recommendations for follow-up are not
the same, not agreed upon or not widely practised, other
numbers would be expected.
Large differences in the numbers of new diagnoses of
AIP and PCT per 100,000 inhabitants were also evident. A
certain degree of diversity in the occurrence of the por-
phyrias between countries is, however, to be expected.
Most mutations of porphyria are private, but several
founder mutations have been described, contributing to
founder effects and higher occurrence of disease in geo-
graphic regions [10-13]. Also, the variation probably
reflects differences in resources used to investigate healthy
at-risk relatives with DNA testing. In some countries,
reported new diagnoses of acute porphyrias consisted al-
most exclusively of presymptomatic cases, while other
centres did not offer presymptomatic testing at all. In
addition, in some countries or areas, intense case finding
projects have already been performed, leaving fewer new
cases to be diagnosed, which could also contribute to the
observed differences.
In Europe, the proportion of new cases of PCT that were
presymptomatic as opposed to symptomatic remained
close to 10% throughout the study period, while the pro-
portion of presymptomatic cases of AIP increased from
57% to 69%. The benefits of presymptomatic testing of
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knowledge about carrier status of a DNA mutation allows
a person to avoid factors known to provoke acute attacks.
Preventing acute attacks can improve quality of life, reduce
the risk of potentially life threatening situations and reduce
long term morbidity [1]. The proportion of centres per-
forming DNA-analyses did not increase during the study-
period, suggesting perhaps a potential for identifying more
at–risk relatives. For the cutaneous porphyria PCT, how-
ever, the benefits of presymptomatic DNA testing are more
questionable. Although the cutaneous symptoms of PCT
can be troublesome, uncomfortable and often long-lasting,
they are not life-threatening and can in most cases be trea-
ted by repeated phlebotomies or low dose chloroquine
treatment [1]. In addition, a clinically indistinguishable
form of non-inheritable PCT exists where the same envir-
onmental factors are necessary to cause disease (iron ex-
cess, hepatitis C infection, alcohol, oestrogens) [12]. Thus,
there is a risk of developing PCT independent of DNA mu-
tation carrier status.
It is important to note that the reported numbers of
new diagnoses in this study are hampered by uncertainties
and should not be interpreted as figures of incidence. Pre-
sumably, many cases of the cutaneous porphyrias such as
PCT, and to some extent EPP, are diagnosed and treated
by dermatologist with little involvement from specialist
porphyria centres, and thus never reported to EPNET.
The reported national coverage of porphyria diagnostics is
therefore thought to be more accurate for the acute por-
phyrias (ALA dehydratase deficiency, AIP, HCP and PV)
than for the cutaneous porphyrias. Even so, a tendency to-
wards overestimating the numbers of new acute porphyria
diagnoses made may be present, as it cannot be ruled out
that the same patient may occasionally be reported from
more than one centre. On the other hand, centres that do
not offer presymptomatic DNA testing probably report
relatively lower numbers of new diagnoses. It is also likely
that in certain regions and countries porphyria services
could be substandard or lacking so that symptomatic
patients are not diagnosed. True incidence rates of clinic-
ally overt inherited porphyrias in European countries have
recently been investigated under the EPNET’s WP7 [14].
The minimum criteria for classification as a specialist
porphyria centre set by EPNET are continuously evalu-
ated and improved when considered necessary. For in-
stance, participation in a relevant EQA program was
introduced as a minimum criterion in 2009, and being
able to differentiate between metal free and zinc-
chelated protoporphyrin was added in 2010. At present,
it is a concern that some centres perform only a limited
amount of some or all laboratory analyses offered each
year, which may compromise both the quality and the
interpretation of the analyses. Therefore, some require-
ments regarding the numbers of yearly analyses per-formed may also, in the future, be included as part of
the minimum criteria for classification as a specialist
porphyria centre.
Conclusions
This study confirms that in 2009, the distribution of por-
phyria services was uneven among EPNET centres and as-
sociate members. However, improvements in the quality
of diagnostic services were observed during 2006 through
2009. The improvements may at least in part be attribut-
able to the cooperation between the participating centres,
the continuous evolvement of and agreement upon best
practice in the field, and the feedback reports provided to
the centres by EPNET, serving as reminders of best prac-
tise. The challenges for the future are first and foremost to
further improve the services of existing EPNET porphyria
centres, to recruit and help improve services of porphyria
centres not already participating in the EPNET, a priority
of EPNET at present, and to encourage the establishment
of porphyria centres in countries or regions lacking in
such services today. In addition, it is crucial to continue
raising awareness of these rare diseases to clinicians out-
side the field. Improvements in porphyria laboratory and
diagnostic services are of little use to patients unless clini-
cians use them.
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